16287-49-3

Basic information

• Product Name: 6-(prop-2-en-1-yl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one
• Synonyms: 5H-Pyrido(2,3-b)(1,5)benzodiazepin-5-one, 6,11-dihydro-6-(2-propenyl)-; 5H-pyrido[2,3-b][1,5]benzodiazepin-5-one, 6,11-dihydro-6-(2-propen-1-yl)-; 5H-Pyrido[2,3-b][1,5]benzodiazepin-5-one, 6,11-dihydro-6-(2-propenyl)-
• CAS NO: 16287-49-3
• Molecular Formula: C₁₅H₁₃N₃O
• Molecular Weight: 251.2832
• Mol File: 16287-49-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 462°C at 760 mmHg
• Flash Point: 233.2°C
• Density: 1.197g/cm³
• Vapor Pressure: 1.03E-08mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: 6-(prop-2-en-1-yl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(prop-2-en-1-yl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one(16287-49-3)
• EPA Substance Registry System: 6-(prop-2-en-1-yl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one(16287-49-3)

Safety Data

• Hazardous Substances Data: 16287-49-3(Hazardous Substances Data)

Upstream product

• 25660-37-1 1-pyridin-2-yl-1H-benzoimidazole 
• 95-54-5 1,2-diamino-benzene 
• 2942-59-8 2-chloronicotinic acid 
• 10189-78-3 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one 

Relevant articles and documents

Benzodiazepine compounds and preparation method thereof

The invention belongs to the technical field of biological medicines, and particularly relates to benzodiazepine compounds and a preparation method thereof. A series of the benzodiazepine compounds provided by the invention are novel in structure, have certain drug potential, and have positive significance when applied to development of novel drugs. According to the invention, an N-heterocyclic bridged benzimidazolium salt is used as a raw material, inherent water in an organic solvent is utilized, and a ring opening-ring expanding reaction is conducted under the action of a catalyst so as toprepare the benzodiazepine compounds with an N-heterocyclic bridged seven-membered ring structure. The method provided by the invention has the advantages of mild conditions, no need for treatment ofthe solvent, simple steps, good regioselectivity and high atom economy.

Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones

Novel pyridobenzodiazepinones (I), pyridobenzodiazepinones (II), and dipyridodiazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM.In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.In general, lipophilic substituents are preferred on the A ring, whereassubstitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings.Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.Additional substituents on the A ring can be readily tolerated.The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridodiazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.